Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Intro slide
- MND/ALS
- Amyotrophic Lateral Sclerosis: core facts
- Pathology of ALS
- Molecular pathology of sporadic ALS
- What is the cause of MND?
- Evidence from genetics
- Genetic basis of ALS-MND
- Familial ALS
- Mutations in SOD1 in familial ALS
- Superoxide dismutase Type 1
- FALS due to SOD1 mutations
- SOD1 activity/disease severity in mouse models
- Transgenic mouse model
- SOD1 mutations and oxidative metabolism
- Natural history in SOD1 mutant mice
- SOD1 gain of function
- Protein aggregation
- Mitochondrial dysfunction
- Mitochondrial dysfunction 2
- Excitotoxicity in ALS
- Neurofilaments
- Role of inflammation
- Role of protein aggregation
- Apoptosis
- Vascular Endothelial Growth Factor (1)
- Vascular Endothelial Growth Factor (2)
- VEGF in human ALS
- VEGF as a potential therapy
- Mouse drug studies
- Positive animal (SOD G93A) trials
- Human therapeutic trials
- Mouse models
- Motor neuron death is a multistep process
- Lessons from other motor neuron disorders
- ALS-Parkinsonian Complex of Guam
- 'ALS2''
- ALS4''
- 'ALS8''
- Other genetic motor neuron disorders
- RNA metabolism and motor neurone disorders
- Mechanisms of motor neurone degeneration
- Future prospects
- Summary
Topics Covered
- Models of MND pathogenesis
- Current understanding on genetic basis of MND
- Animal and cellular models
- Pathways of motor neurone vulnerability
- Abnormal protein handling
- Mitochondrial dysfunction
- Abnormalities in axonal transport and apoptosis
- Current limitations in treatment
- Role of genetic research in identifying biological basis
- Future directions and developing biomarkers
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Talbot, K. (2007, October 1). Motor neurone disease: molecular basis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 12, 2024, from https://doi.org/10.69645/HEZE7571.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Kevin Talbot has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.